BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hyder O, Dodson RM, Weiss M, Cosgrove DP, Herman JM, Geschwind JH, Kamel IR, Pawlik TM. Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma. J Gastrointest Surg. 2013;17:1774-1783. [PMID: 23943387 DOI: 10.1007/s11605-013-2302-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Wiebel JL, Banerjee M, Muenz DG, Worden FP, Haymart MR. Trends in imaging after diagnosis of thyroid cancer. Cancer 2015;121:1387-94. [PMID: 25565063 DOI: 10.1002/cncr.29210] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
2 Banerjee M, Wiebel JL, Guo C, Gay B, Haymart MR. Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence. BMJ 2016;354:i3839. [PMID: 27443325 DOI: 10.1136/bmj.i3839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
3 Talwalkar JA. Health services and policy research in hepatology. Curr Opin Gastroenterol 2014;30:272-8. [PMID: 24662844 DOI: 10.1097/MOG.0000000000000064] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
4 Onuma AE, Palmer Kelly E, Chakedis J, Paredes AZ, Tsilimigras DI, Wiemann B, Johnson M, Merath K, Akgul O, Cloyd J, Pawlik TM. Patient preferences on the use of technology in cancer surveillance after curative surgery: A cross-sectional analysis. Surgery 2019;165:782-8. [PMID: 30770135 DOI: 10.1016/j.surg.2018.12.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Mehta R, Tang Qinghe, Tsilimigras DI, Paredes A, Dillhoff M, Cloyd JM, Ejaz A, Tsung A, Spolverato G, Pawlik TM. Long-term outcomes after resection of alcohol-related versus hepatitis-related hepatocellular carcinoma: A SEER-Medicare database analysis. Am J Surg 2021;222:167-72. [PMID: 33131693 DOI: 10.1016/j.amjsurg.2020.10.033] [Reference Citation Analysis]
6 Côté MJ, Smith MA. Forecasting the demand for radiology services. Health Syst (Basingstoke) 2018;7:79-88. [PMID: 31214340 DOI: 10.1080/20476965.2017.1390056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 90.0] [Reference Citation Analysis]
8 Yoon JH, Goo YJ, Lim CJ, Choi SK, Cho SB, Shin SS, Jun CH. Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2020; 26(32): 4833-4845 [PMID: 32921960 DOI: 10.3748/wjg.v26.i32.4833] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mirdad RS, Madison Hyer J, Diaz A, Tsilimigras DI, Azap RA, Paro A, Pawlik TM. Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough? J Surg Oncol 2021;123:1568-77. [PMID: 33596330 DOI: 10.1002/jso.26433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sun X, Li L, Lyu N, Mu L, Lai J, Zhao M. Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification. Cancer Imaging 2020;20:42. [PMID: 32611383 DOI: 10.1186/s40644-020-00319-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Liu W, Zheng Y, Zou R, Shen J, He W, Yang Z, Zhang Y, Li B, Yuan Y. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer 2018;18:1186. [PMID: 30497418 DOI: 10.1186/s12885-018-5069-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
12 Gray SH, White JA, Li P, Kilgore ML, Redden DT, Abdel Aal AK, Simpson HN, McGuire B, Eckhoff DE, Dubay DA. A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy. J Vasc Interv Radiol 2017;28:231-237.e2. [PMID: 27939085 DOI: 10.1016/j.jvir.2016.09.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]